Hervé Hoppenot, Incyte CEO
October 3, 2022 07:27 AM EDT
Deals

In­cyte pays out $70M to get hands on Medicxi-backed vi­tili­go biotech

Paul Schloesser

Associate Editor

The M&A wheels keep on turn­ing in biotech — and this time it’s In­cyte that gets to do the deal­mak­ing.

The Delaware biotech put out word …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Vice President, Biology & Translational Research

Gondolabio

Palo Alto, CA, USA

TRENDING NOW

Fed­er­al judge nix­es FDA's lab-de­vel­oped test rule, says it ex­ceed­ed agen­cy's au­thor­i­ty

What’s next af­ter Marks? At FDA, ques­tions over more top ex­its and fu­ture vi­sion for drug agency

Marks’ ex­it at FDA rat­tles an al­ready tee­ter­ing biotech in­dus­try

Mer­ck’s PAH drug cuts risk of se­ri­ous events by 76% in tri­al stopped for ef­fi­ca­cy

Lil­ly's heart dis­ease drug could be dosed as lit­tle as once a year, study shows

sponsored

End­points we­bi­nar: In­side the “One Lon­za” strat­e­gy: Re-en­gi­neer­ing the fu­ture of CD­MO

A service from the Financial Times